Bavarian Biotech Inside Shaping the Future of Medicine.

Transcription

1 Bavarian Biotech Inside Shaping the Future of Medicine

2 Bio M accelerating biomedical innovation Vision Bavaria the place for the medicine of the future Mission Bio M recognizes the challenges of the medicine of the future and supports its development by identifying and connecting the appropriate partners from science, industry, medicine and finance. Bio M accompanies the innovation process by developing and providing target-oriented measures and custom-fit instruments.

3 History of the Munich Biotech Cluster 1984 Foundation of the Munich Gene Center st Munich biotech company 1996 Munich is one of the winners ( 25 mio) in the BioRegio Contest of the BMBF* 1997 Foundation of Bio M as the central contact point for biotechnology in the Greater Munich Area 2007 Munich is one of the winners ( 5 mio) in the BioIndustry 2021 Contest (industrial biotechnology) of the BMBF* 2010 Munich is one of the winners ( 40 mio) in the Leading Edge Cluster Competition of the BMBF* 2017 Bio M and the Munich Biotech Cluster celebrating 20 years of growth and innovation *BMBF = Federal Ministry of Education and Research

4 Bio M Partner for Sustainable Innovation SMEs Funding Partnering Business Development Networking Professional Training Internationalization Events Academia Big Pharma Partnering Seminars & Workshops Networking Events Scouting & Incubation Start-up Consulting Funding

5 Bavaria a leading biotech ecosystem biotech companies: 1997: : 234 employees in biotech: 1997: 2, : 14,500 ongoing clinical trials: 1997: : 125 approved drugs: 1997: : 9 (derived from Munich based biotech SMEs) > 4.2 bn private investments in SME since 1997 > 2.0 bn investments in infrastructure Bio M support since 1997 a top location, with a dynamic and experienced network of (serial) entrepreneurs, investors and innovators

6 Number of Companies Strong in Therapeutics and Diagnostics Companies SME Internation al Subsidiarie s

7 Supporting BioEntrepreneurs inqlab Mentor Circle Bio Angels Boot Camp BioEntrepreneur Lounge Pitch Doctor m 4 Award

8 Jobs Growth rate 2016/2017: 8% Employees in Research SME Internationa l Subsidiarie s

9 Drug Pipeline (SME only) Strong Focus on Cancer Therapeutics Number of Clinical Trials (Phases I-III) Number of Studies by Phase and Indication Cancer Infectious Diseases Autoimmune Diseases CNS Diseases Cardiovascular Diseases Other

10 Approved drugs from the Munich Biotech Cluster IMVANEX / IMVAMUNE : active immunization smallpox vaccine Removab (Catumaxumab): EpCAM and CD3 targeting monoclonal antibody to treat malignant ascites ATG-Fresenius S: antibody-based immunosuppressant used in organ and stem cell transplantation Blincyto (Blinatumomab): BiTE antibody for the treatment of ALL Veregen : treatment of external genital warts based on green tea extract Oracea : dermatological product for the treatment of rosacea. Eligard : for the treatment of hormone-dependent prostate cancer EndolucinBeta : 177 Lu radiopharmaceutic precurser to be coupled with carrier molecules for targeted radionuclide therapy Tremfya (Guselkumab): antibody for the treatment of moderate to severe plaque psoriasis

11 Approved drugs from the Munich Biotech Cluster IMVANEX / IMVAMUNE : active immunization smallpox vaccine Removab (Catumaxumab): EpCAM and CD3 targeting monoclonal antibody to treat malignant ascites ATG-Fresenius S: antibody-based immunosuppressant used in organ and stem cell transplantation Blincyto (Blinatumomab): BiTE antibody for the treatment of ALL Veregen : treatment of external genital warts based on green tea extract Oracea : dermatological product for the treatment of rosacea. Eligard : for the treatment of hormone-dependent prostate cancer EndolucinBeta : 177 Lu radiopharmaceutic precurser to be coupled with carrier molecules for targeted radionuclide therapy Tremfya (Guselkumab): antibody for the treatment of moderate to severe plaque psoriasis

12 Approved drugs from the Munich Biotech Cluster IMVANEX / IMVAMUNE : active immunization smallpox vaccine Removab (Catumaxumab): EpCAM and CD3 targeting monoclonal antibody to treat malignant ascites ATG-Fresenius S: antibody-based immunosuppressant used in organ and stem cell transplantation Blincyto (Blinatumomab): BiTE antibody for the treatment of ALL Veregen : treatment of external genital warts based on green tea extract Oracea : dermatological product for the treatment of rosacea. Eligard : for the treatment of hormone-dependent prostate cancer EndolucinBeta : 177 Lu radiopharmaceutic precurser to be coupled with carrier molecules for targeted radionuclide therapy Tremfya (Guselkumab): antibody for the treatment of moderate to severe plaque psoriasis

13 Bavarian Biotech International Connections

14 P4 Medicine Healthcare of the Future Predictive Biomarkers - DNA/RNA-omics - Proteomics Preventive Life Style and Treatment - Phenylketonuria - Diabetes - Cancer Participatory Informed Decisions by informed Patients $ Genome Personalized Stratification of Patients - Herceptin - Erbitux -...

15 DigiMed Bavaria Lighthouse Project for P4 Medicine: predictive, preventive, personalized, participatory Focus on atherosclerosis, the disease causing most deaths in the industrial world Funded ( 25 Mio.) by the Bavarian Ministry of Health Duration: 5 years diagnosis, treatment, prevention Individuelles Risiko MD / scientist cohort / individual data warehouse genome, transcriptome, proteome, metabolome lab data, histology, development

16 Bavarian Cancer Research Center Universitätsklinikum Würzburg Universitätskliniken Erlangen/Nürnberg Universitätsklinikum Regensburg Klinikum rechts der Isar (TU München) Universitätskliniken München Klinikum Großhadern (LMU München)

17 THANK YOU Bio M Biotech Cluster Development GmbH Am Klopferspitz 19a Martinsried, Munich Germany info@bio-m.org Phone: +49 (0)